https://arolstar52-zhtest.hf.space/index.php?action=history&feed=atom&title=2C-I
2C-I - 版本历史
2026-07-19T20:22:31Z
本wiki上该页面的版本历史
MediaWiki 1.43.9
https://arolstar52-zhtest.hf.space/index.php?title=2C-I&diff=4659760&oldid=prev
imported>Yyfroy：修飾語句
2025-08-15T10:25:13Z
<p>修飾語句</p>
<p><b>新页面</b></p><div>{{Infobox drug<br />
| Verifiedfields = verified<br />
| Watchedfields = verified<br />
| verifiedrevid = 477216266<br />
| drug_name = <br />
| image = 2C-I2DACS.svg<br />
| image_class = skin-invert-image<br />
| width = 200px<br />
| image2 = 2C-I-3d-sticks.png<br />
| width2 = 200px<br />
<br />
<!-- Clinical data --><br />
| pronounce = <br />
| tradename = <br />
| Drugs.com = <br />
| MedlinePlus = <br />
| licence_CA = <br />
| licence_EU = <br />
| DailyMedID = <br />
| licence_US = <br />
| pregnancy_AU = <br />
| pregnancy_category = <br />
| dependency_liability = <br />
| addiction_liability = <br />
| routes_of_administration = <br />
| class = <br />
| ATC_prefix = <br />
| ATC_suffix = <br />
<br />
<!-- Legal status --><br />
| legal_AU = Schedule 9<br />
| legal_BR = F2<br />
| legal_CA = Schedule III<br />
| legal_UK = Class A<br />
| legal_US = Schedule I<br />
| legal_status = <br />
<br />
<!-- Pharmacokinetic data --><br />
| bioavailability = <br />
| protein_bound = <br />
| metabolism = <br />
| metabolites = <br />
| onset = <br />
| elimination_half-life = <br />
| duration_of_action = <br />
| excretion = <br />
<br />
<!-- Identifiers --><br />
| CAS_number_Ref = {{cascite|correct|CAS}}<br />
| CAS_number = 69587-11-7<br />
| CAS_supplemental = <br />
| PubChem = 10267191<br />
| PubChemSubstance = <br />
| IUPHAR_ligand = <br />
| DrugBank = <br />
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}<br />
| ChemSpiderID = 8442670<br />
| UNII_Ref = {{fdacite|correct|FDA}}<br />
| UNII = S35362848V<br />
| KEGG_Ref = {{keggcite|correct|kegg}}<br />
| KEGG = C22776<br />
| ChEBI = <br />
| ChEMBL_Ref = {{ebicite|correct|EBI}}<br />
| ChEMBL = 338297<br />
| NIAID_ChemDB = <br />
| PDB_ligand = <br />
| synonyms = <br />
<br />
<!-- Chemical data --><br />
| IUPAC_name = 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine<br />
| C=10 | H=14 | I=1 | N=1 | O=2<br />
| SMILES = Ic1cc(OC)c(cc1OC)CCN<br />
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}<br />
| StdInChI = 1S/C10H14INO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3<br />
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}<br />
| StdInChIKey = PQHQBRJAAZQXHL-UHFFFAOYSA-N<br />
<br />
<!-- Physical data --><br />
| melting_point = 246<br />
}}<br />
'''{{PAGENAME}}'''（'''2,5-二甲氧基-4-碘苯乙胺'''{{langx|en|2,5-dimethoxy-4-iodophenethylamine}}）是一种[[氮化合物|含氮]][[有机碘化合物]]，分子式[[C10H14INO2|{{chem2|C10H14INO2}}]]，属于[[2,5-二甲氧基苯乙胺衍生物]]（2C类化合物），由[[亚历山大·舒尔金]]首次[[化学合成|合成]]，并在其书《[[PiHKAL]]》中讨论了其性质，可作为[[迷幻药物]]<ref>{{cite journal | vauthors = Bosak A, LoVecchio F, Levine M | title = Recurrent seizures and serotonin syndrome following "2C-I" ingestion | journal = Journal of Medical Toxicology | volume = 9 | issue = 2 | pages = 196–198 | date = June 2013 | pmid = 23378129 | pmc = 3657032 | doi = 10.1007/s13181-013-0287-x }}</ref>。<br />
<br />
==参考文献==<br />
{{reflist}}<br />
<br />
==外部链接==<br />
* [https://isomerdesign.com/pihkal/explore/33 2C-I - Isomer Design]<br />
* [https://psychonautwiki.org/wiki/2C-I 2C-I - PsychonautWiki]<br />
* [http://www.erowid.org/chemicals/2ci/2ci.shtml Erowid 2C-I Vault]<br />
* [http://www.erowid.org/library/books_online/pihkal/pihkal033.shtml 2C-I Entry in PiHKAL]<br />
* [http://pihkal.info/read.php?domain=pk&id=33 2C-I Entry in PiHKAL • info]<br />
* [https://tripsitter.com/2ci/ 2C-I: An Obscure, But Powerful Research Chemical - Tripsitter]<br />
<br />
[[Category:2C系列化合物]]<br />
[[Category:策划药]]<br />
[[Category:TAAR1激动剂]]</div>
imported>Yyfroy